ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

John Ultmann, Chicago’s Outspoken Director, Heads In Retirement

August 30, 1991

Outcome Of Prostate Cancer Surgery Depends On Experience Of Surgeon

August 31, 2007

In Brief: NCI To Leave Blair, Landlow Building; House To Hold Hearings March 5 On NCI’s 1998 Budget

February 13, 1987

House Plan Promises $3.5 Billion For NIH; Cooperative Groups May Get AHRQ Funds

January 23, 2009

Cancer Incidence Rates Climb In HIV-Positive Female Populations

April 27, 2012

Also in this 12-page issue: NCI’s Lance Liotta and FDA’s Emanuel Petricoin to move to George Mason University.

March 11, 2005